share_log

Insmed | 10-Q: Q2 2024 Earnings Report

Insmed | 10-Q: Q2 2024 Earnings Report

Insmed | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/08 19:04

Moomoo AI 已提取核心信息

Insmed reported Q2 2024 financial results, with ARIKAYCE net sales increasing 17% year-over-year to $90.3 million. US sales grew 10.6% to $63.8 million, while Japan sales rose 35.4% to $21.1 million. The company plans to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results.R&D expenses decreased 25.5% to $146.7 million, primarily due to the absence of a $76.5 million non-cash asset acquisition cost in Q2 2023. This was partially offset by higher compensation expenses and a $12.5 million milestone payment to AstraZeneca. SG&A expenses increased 26.2% to $106.6 million, driven by higher headcount and commercial readiness activities for brensocatib.Insmed ended Q2 with $1.25 billion in cash and cash equivalents, bolstered by a $713.2 million equity offering in May 2024. The company expects to initiate a Phase 3 study of TPIP in PH-ILD in 2025 and anticipates topline results from a Phase 2 TPIP study in PAH in 2025. Management believes current funds are sufficient to meet financial needs for at least the next 12 months.
Insmed reported Q2 2024 financial results, with ARIKAYCE net sales increasing 17% year-over-year to $90.3 million. US sales grew 10.6% to $63.8 million, while Japan sales rose 35.4% to $21.1 million. The company plans to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results.R&D expenses decreased 25.5% to $146.7 million, primarily due to the absence of a $76.5 million non-cash asset acquisition cost in Q2 2023. This was partially offset by higher compensation expenses and a $12.5 million milestone payment to AstraZeneca. SG&A expenses increased 26.2% to $106.6 million, driven by higher headcount and commercial readiness activities for brensocatib.Insmed ended Q2 with $1.25 billion in cash and cash equivalents, bolstered by a $713.2 million equity offering in May 2024. The company expects to initiate a Phase 3 study of TPIP in PH-ILD in 2025 and anticipates topline results from a Phase 2 TPIP study in PAH in 2025. Management believes current funds are sufficient to meet financial needs for at least the next 12 months.
Insmed公布了2024年第二季度财务结果，ARIKAYCE净销售额同比增长17%，达到9030万美金。美国销售额增长10.6%，达6380万美金，而日本销售额上升35.4%，达2110万美金。公司计划在2024年第四季度提交有关支气管扩张症的brensocatib新药申请，继ASPEN第三阶段试验结果积极之后。研发支出减少25.5%，降至14670万美金，主要是由于2023年第二季度没有7650万美金的非现金资产收购成本。部分由于补偿支出增加以及向阿斯利康支付的1250万美金里程碑付款而抵消。销售、一般及行政费用增长26.2%，达到10660万美金，推动因素包括员工人数增加和针对brens...展开全部
Insmed公布了2024年第二季度财务结果，ARIKAYCE净销售额同比增长17%，达到9030万美金。美国销售额增长10.6%，达6380万美金，而日本销售额上升35.4%，达2110万美金。公司计划在2024年第四季度提交有关支气管扩张症的brensocatib新药申请，继ASPEN第三阶段试验结果积极之后。研发支出减少25.5%，降至14670万美金，主要是由于2023年第二季度没有7650万美金的非现金资产收购成本。部分由于补偿支出增加以及向阿斯利康支付的1250万美金里程碑付款而抵消。销售、一般及行政费用增长26.2%，达到10660万美金，推动因素包括员工人数增加和针对brensocatib的商业准备活动。Insmed在第二季度结束时拥有现金及现金等价物12.5亿美金，得益于2024年5月进行的71320万美金的股权融资。公司预计将在2025年启动TPIP在PH-ILD的第三阶段研究，并预期在2025年从PAH的阶段2 TPIP研究中获取顶线结果。管理层认为当前的所有基金类型足以满足未来至少12个月的财务需求。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

独立文件10  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间